ER NEWS
Aethlon Medical (Nasdaq: AEMD) announced financial results for the fiscal year ending March 31, 2024, and provided a corporate update. The company continues the clinical development of its Hemopurifier® for cancer and infectious diseases, receiving ethics approval for a clinical trial in Australia.
Financially, Aethlon reported a net loss of $12.2 million, a slight increase from the previous year's $12 million.
Operating expenses rose marginally to $12.6 million from $12.5 million, driven by increased payroll costs.
The current cash balance stands at $9.1 million.
Efforts are ongoing to secure approvals for additional trial sites in Australia and India, with patient enrollment expected by late 2024.
Aethlon Medical FY 2024 GAAP EPS $(4.86) Beats $(5.22) Estimate
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1076Followers
68Following
7416Visitors
Follow